00:20 , Sep 15, 2018 |  BC Extra  |  Company News

FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine

FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved in the indication. Teva...
21:51 , Sep 14, 2018 |  BioCentury  |  Finance

Coda’s chemogenetic control

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic. Seed investors MPM Capital...
17:28 , Sep 14, 2018 |  BC Week In Review  |  Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
15:18 , Sep 14, 2018 |  BC Week In Review  |  Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
13:08 , Sep 12, 2018 |  BC Extra  |  Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
00:00 , Sep 8, 2018 |  BioCentury  |  Product Development

Data distribution

TransCelerate BioPharma Inc. is taking its data sharing initiative to the next level with a new platform that will integrate clinical and preclinical data sets in a single repository and provide new analytical tools. DataCelerate,...
17:49 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc. (NASDAQ:AMGN),...
23:30 , Sep 5, 2018 |  BC Extra  |  Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm Wednesday, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc....
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
23:11 , Aug 28, 2018 |  BC Extra  |  Company News

Management tracks: BMS, Roche

Bristol-Myers Squibb Co. (NYSE:BMY) said Christopher Boerner will become EVP and Chief Commercial Officer. He succeeds Murdo Gordon, who departed the company last month to become EVP of global commercial operations at Amgen Inc. (NASDAQ:AMGN)...